Clinical progress of leucine-rich glioma inactivated-1 antibody-mediated encephalitis

Abstract

Leucine-rich glioma inactivated-1 (LGI-1) antibody-mediated encephalitis is a subtype of autoimmune encephalopathy associated with antibody against neuronal plasma membrane proteins ADAM23 binding protein LGI-1. The main symptoms of this disease are characterized by seizures, faciobrachial dystonic seizures, cognitive deficits, neuropsychiatric disturbances, and intractable hyponatremia. The disease diagnosis mainly depends on positive expression of LGI1 antibody in serum or cerebrospinal fluid. Early diagnosis combined with immunotherapy can apparently improve prognosis and reduce the risk of disease recurrence. However, due to the delayed diagnosis or misdiagnosis, the patients always result in poor prognosis. The objective of this review is to raise awareness of LGI-1 antibody encephalitis. Thus, in this study, we summarize the etiology, pathogenesis, clinical presentations, imaging, diagnosis, treatments and prognoses of this disease based on the latest research progress to improve the diagnosis and curative effect. \n \n \nKey words: \nLeucine-rich glioma inactivated-1;\xa0Faciobrachial dystonic seizure;\xa0Hyponatremia;\xa0Positron emission tomography;\xa0Immunotherapy